CAP-CD56+CD271+ BMSCs Exos-PVA/SA hydrogel

Intervention

1 paper1 finding

  • 1 lab in 1 country
  • Funders: Education Department of Hunan Province and 2 more
  • Animals1

Outcomes

1

Senescence markers

downin humans1

1 study
  1. CAP-CD56+CD271+ BMSCs Exos-PVA/SA hydrogel decreases senescence markers in humans.

    “Implantation of the integrated CAP-Exos-PVA/SA system markedly improved osteoarthritis cartilage structure, increased matrix deposition, and suppressed the expression of matrix metalloproteinase-13 (MMP-13) and senescence markers (p16/p21/p53).”

    Animalsosteoarthritis

    CAP-CD56⁺CD271⁺ BMSCs exos-loaded PVA/SA sustained-release hydrogel attenuates chondrocyte senescence and ameliorates lumbar facet joint osteoarthritis

    Bioactive materials6 Nov 2025

More on Senescence markers

Latest

Nov 2025: 1Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 01 in 12 months